Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prognostic Value of the Bradykinin-degradating Enzymes Activities on the Relapse Risk of Angiotensin-Converting Enzyme Inhibitors-associated Angioedema

NCT04763577 is registered in ClinicalTrials.gov with University Hospital, Grenoble as lead sponsor.

NCT NCT04763577
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04763577 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prognostic Value of the Bradykinin-degradating Enzymes Activities on the Relapse Risk of Angiotensin-Converting Enzyme Inhibitors-associated Angioedema
Lead sponsor
University Hospital, Grenoble
Phase
Observational
Overall status
Recruiting
Start date
October 27, 2021
Completion date
October 26, 2025
Enrollment
243 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

angio-oedema caused by angiotensin-converting-enzyme inhibitor